Venus Remedies Limited has secured five marketing authorisations across Kazakhstan, Peru, Kuwait, and Argentina. This development strengthens the company's international presence and expands access to its pharmaceutical portfolio in key global regions.

Approvals by market

The regulatory clearances cover specific critical-care injectables in four distinct geographies:

Strategic expansion

The company stated that these approvals mark a significant step in its international growth strategy. Saransh Chaudhary, Executive Director of Venus Remedies and CEO of Venus Medicine Research Centre (VMRC), noted that the focus remains on building a strong global portfolio to make quality pharmaceutical solutions accessible worldwide.

Aditi K. Chaudhary, President of International Business at Venus Remedies, highlighted that the strategy centres on expanding reach in high-potential markets while strengthening the product portfolio through regulatory excellence and differentiated offerings.

Global footprint context

Venus Remedies is a leader in critical-care injectables with an established international footprint in over 100 countries. The new authorisations reinforce the company's continued focus on expanding its export portfolio across diverse geographies and building opportunities for sustainable international growth.

Venus Remedies declared a final dividend of ₹10 per equity share during its 37th Annual General Meeting (AGM) held on August 20, 2026. The company confirmed that all 12 resolutions were passed with the requisite majority, as per the scrutinizer’s report dated August 21, 2026.

Key Resolutions Passed

Shareholders approved several ordinary and special resolutions, including the adoption of standalone and consolidated audited financial statements for the fiscal year ended March 31, 2026. The Board presented an overview of the company’s performance during FY25-26 and outlined future growth prospects.

Corporate Governance Changes

Shareholders approved special resolutions to alter the Memorandum of Association (MOA) and adopt new Articles of Association (AOA). The revision in the MOA was done primarily to align the Object Clause with the provisions of the Companies Act, 2013. The Main Objects and Objects Incidental or Ancillary to the Attainment of the Main Objects were updated to suitably align with the company's current business practices and proposed business activities. The principal business activities remain unchanged, with the company continuing to operate in the pharmaceutical sector.

The new AOA was adopted as per Table-F of Schedule I of the Companies Act, 2013, replacing the existing AOA based on the Companies Act, 1956, which contained redundant provisions inconsistent with the current Act. The remuneration of ₹1,10,000 per annum for cost auditors for FY26-27 was also ratified.

Board Appointments

The AGM approved key leadership transitions and reappointments, effective from specific dates disclosed in the regulatory filing:

• New Appointment: Mr. Saransh Chaudhary was appointed as Executive Director (Whole Time Director) for a five-year term starting May 26, 2026. An alumnus of the University of Oxford, he currently serves as CEO of Venus Medicine Research Centre (VMRC) and President – Global Critical Care and Consumer Healthcare.
• Independent Directors: Dr. Gurminder Singh Bedi was appointed as Non-Executive Independent Director for five years starting May 26, 2026. Dr. (Mrs.) Savita Gupta was reappointed for a second five-year term starting December 30, 2026.
• Joint Managing Director: Dr. (Mrs.) Manu Chaudhary was reappointed as Joint Managing Director for five years starting October 1, 2026. She heads the R&D and operations of the company.
• Reappointment: Mr. Ashutosh Jain and Mr. Peeyush Jain were reappointed as directors liable to retire by rotation.

Voting Results

The total number of shareholders on the record date of August 13, 2026, was 23,489. A total of 59 public members attended the meeting via video conferencing, while promoters voted exclusively through remote e-voting.

While all resolutions passed, the appointment of directors and the alteration of corporate documents saw dissenting votes primarily from public institutions. For instance, public institutions voted against the reappointment of certain independent directors and the new Articles of Association, though promoter support ensured passage.

Meeting Proceedings

Fifty-nine members attended the virtual meeting, establishing the requisite quorum. Electronic voting was facilitated by M/s. MUFG Intime India Pvt. Ltd., with the remote e-voting period running from August 17, 2026, to August 19, 2026. Mr. Prince Chadha served as the Scrutinizer for the voting process.

During the question-and-answer session, seven registered speakers raised queries regarding financials, products, and strategies. The Board addressed these concerns before concluding the proceedings. The final voting results have been submitted in accordance with Regulation 44(3) of the SEBI Listing Regulations and Section 108 of the Companies Act, 2013.